外泌体长链非编码RNA在膀胱癌中的研究进展

顾君; 何泽喜; 栾婷; 王海峰; 王剑松; 丁明霞

doi:10.12259/j.issn.2095-610X.S20220110

外泌体长链非编码RNA在膀胱癌中的研究进展

doi: 10.12259/j.issn.2095-610X.S20220110

昆明医科大学第二附属医院泌尿外科，云南省泌尿外科研究所，云南昆明　650101

基金项目: 国家自然科学基金资助项目（82060464）；云南省高校科技创新团队基金资助项目[云教（2019）58]

详细信息

作者简介:
顾君（1993～），男，浙江宁波人，在读硕士研究生，主要从事泌尿外科恶性肿瘤研究工作

通讯作者:
丁明霞，E-mail：dmx7166@126.com

中图分类号: R737.14
计量
- 文章访问数: 4121
- HTML全文浏览量: 2424
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-07
- 网络出版日期: 2021-12-20
- 刊出日期: 2022-01-15

Research Progress of Exosomes-derived Long Non-coding RNA in Bladder Cancer

Dept. of Urology，The 2nd Affiliated Hospital of Kunming Medical University， Yunnan Institute of Urology，Kunming Yunnan 650101，China

摘要

摘要: 膀胱癌是最常见的泌尿系肿瘤之一，具有较高的发病率和复发率，开发一种高灵敏度和高特异性的无创性体外诊断检测技术对于膀胱癌的诊断和治疗具有重要的临床价值。外泌体是一种由许多细胞分泌的细胞外囊泡，通过递送细胞内信号物质（如蛋白质，核酸，非编码RNA等）在细胞间通讯中发挥关键作用。越来越多研究表明外泌体来源的长链非编码RNA在膀胱癌发生发展中发挥重要的调控作用，能够有效地反映肿瘤的进展和预后情况，有望成为一种新的肿瘤标记物。因此就外泌体来源的长链非编码RNA在膀胱癌发生发展及诊断方面的研究进展进行综述。
- 外泌体 /
- 长链非编码RNA /
- 膀胱癌
Abstract: Bladder cancer is one of the most common urinary tumors with the high morbidity and recurrence rate. It is of great clinical value to develop a non-invasive detection technique with the high sensitivity and specificity in vitro for the diagnosis and treatment of bladder cancer. Exosomes are extracellular vesicles secreted by many cells and play a key role in intercellular communication by delivering intracellular signaling substances （such as proteins, nucleic acids, non-coding RNAs, etc.）. More and more studies have shown that exosomes-derived long non-coding RNA plays an important regulatory role in the development and progression of bladder cancer and can effectively reflect the progression and prognosis of tumors, which is expected to become a new tumor marker. Therefore, this paper reviews the research progress of exosomes-derived long non-coding RNA in the development and diagnosis of bladder cancer.
- Exosomes /
- Long non-coding RNA /
- Bladder cancer

HTML全文

参考文献(50)

[1]	Kelly J D,Tan W S,Porta N,et al. BOXIT-A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004)[J]. Eur Urol,2019,75(4):593-601. doi: 10.1016/j.eururo.2018.09.020
[2]	Tan W S,Tan W P,Tan M Y,et al. Novel urinary biomarkers for the detection of bladder cancer:A systematic review[J]. Cancer Treat Rev,2018,69(3):39-52.
[3]	Babjuk M,Bohle A,Burger M,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:Update 2016[J]. Eur Urol,2017,71(3):447-461. doi: 10.1016/j.eururo.2016.05.041
[4]	Kamat A M,Hahn N M,Efstathiou J A,et al. Bladder cancer[J]. Lancet,2016,388(10061):2796-2810. doi: 10.1016/S0140-6736(16)30512-8
[5]	Lokeshwar V B, Habuchi T, Grossman H B, et al. Bladder tumor markers beyond cytology: International consensus panel on bladder tumor markers[J]. Urology, 2005, 66（6 Suppl 1）: 35-63.
[6]	Chao D,Freedland S J,Pantuck A J,et al. Bladder cancer 2000:Molecular markers for the diagnosis of transitional cell carcinoma[J]. Rev Urol,2001,3(2):85-93.
[7]	Nabet B Y, Qiu Y, Shabason J E, et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer[J]. Cell, 2017, 170（2）: 352-366 e313.
[8]	Jiang L,Vader P,Schiffelers R M. Extracellular vesicles for nucleic acid delivery:Progress and prospects for safe RNA-based gene therapy[J]. Gene Ther,2017,24(3):157-166. doi: 10.1038/gt.2017.8
[9]	Navakanitworakul R,Hung W T,Gunewardena S,et al. Characterization and small RNA content of extracellular vesicles in follicular fluid of developing bovine antral follicles[J]. Sci Rep,2016,6(9):25486.
[10]	Tkach M,Thery C. Communication by extracellular vesicles:Where we are and where we need to go[J]. Cell,2016,164(6):1226-1232. doi: 10.1016/j.cell.2016.01.043
[11]	Li M,Zeringer E,Barta T,et al. Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers[J]. Philos Trans R Soc Lond B Biol Sci,2014,369(1652):20130502. doi: 10.1098/rstb.2013.0502
[12]	Zhou W,Fong M Y,Min Y,et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis[J]. Cancer Cell,2014,25(4):501-515. doi: 10.1016/j.ccr.2014.03.007
[13]	Yang L,Wu X H,Wang D,et al. Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro[J]. Mol Med Rep,2013,8(4):1272-1278. doi: 10.3892/mmr.2013.1634
[14]	Xu X D,Wu X H,Fan Y R,et al. Exosome-derived microRNA-29c induces apoptosis of BIU-87 cells by down regulating BCL-2 and MCL-1[J]. Asian Pac J Cancer Prev,2014,15(8):3471-3476. doi: 10.7314/APJCP.2014.15.8.3471
[15]	Beckham C J,Olsen J,Yin P N,et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression[J]. J Urol,2014,192(2):583-592. doi: 10.1016/j.juro.2014.02.035
[16]	Ringuette Goulet C,Bernard G,Tremblay S,et al. Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFβ signaling[J]. Mol Cancer Res,2018,16(7):1196-1204. doi: 10.1158/1541-7786.MCR-17-0784
[17]	Franzen C A,Blackwell R H,Todorovic V,et al. Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes[J]. Oncogenesis,2015,4(8):e163. doi: 10.1038/oncsis.2015.21
[18]	Goulet C R,Champagne A,Bernard G,et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling[J]. BMC Cancer,2019,19(1):137. doi: 10.1186/s12885-019-5353-6
[19]	Shan G,Zhou X,Gu J,et al. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/beta-catenin pathway and upregulating PTEN[J]. Cell Oncol (Dordr),2021,44(1):45-59. doi: 10.1007/s13402-020-00500-0
[20]	Jeppesen D K,Nawrocki A,Jensen S G,et al. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors[J]. Proteomics,2014,14(6):699-712. doi: 10.1002/pmic.201300452
[21]	Pan J,Li X,Wu W,et al. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells[J]. Cancer Lett,2016,382(1):64-76. doi: 10.1016/j.canlet.2016.08.015
[22]	Yang C,Li X,Wang Y,et al. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells[J]. Gene,2012,496(1):8-16. doi: 10.1016/j.gene.2012.01.012
[23]	Wang X,Gong Y,Jin B,et al. Long non-coding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells[J]. Oncol Rep,2014,32(3):1281-1290. doi: 10.3892/or.2014.3309
[24]	Wang X-S,Zhang Z,Wang H-C,et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma[J]. Clin Cancer Res,2006,12(16):4851-4858. doi: 10.1158/1078-0432.CCR-06-0134
[25]	Wang F,Li X,Xie X,et al. UCA1,a non-protein-coding RNA up-regulated in bladder carcinoma and embryo,influencing cell growth and promoting invasion[J]. FEBS Lett,2008,582(13):1919-1927. doi: 10.1016/j.febslet.2008.05.012
[26]	Xue M,Chen W,Xiang A,et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1[J]. Mol Cancer,2017,16(1):143. doi: 10.1186/s12943-017-0714-8
[27]	Xue M,Pang H,Li X,et al. Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway[J]. Cancer Sci,2016,107(1):18-27. doi: 10.1111/cas.12844
[28]	Zheng R,Du M,Wang X,et al. Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression[J]. Mol Cancer,2018,17(1):143. doi: 10.1186/s12943-018-0880-3
[29]	Huang C S,Ho J Y,Chiang J H,et al. Exosome-derived LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells[J]. Cells,2020,9(6):1419. doi: 10.3390/cells9061419
[30]	Yan L,Wang P,Fang W,et al. Cancer-associated fibroblasts-derived exosomes-mediated transfer of LINC00355 regulates bladder cancer cell proliferation and invasion[J]. Cell Biochem Funct,2020,38(3):257-265. doi: 10.1002/cbf.3462
[31]	He W,Zhong G,Jiang N,et al. Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis[J]. J Clin Invest,2018,128(2):861-875. doi: 10.1172/JCI96218
[32]	Chen C,He W,Huang J,et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment[J]. Nat Commun,2018,9(1):3826. doi: 10.1038/s41467-018-06152-x
[33]	Chen C,Luo Y,He W,et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer[J]. J Clin Invest,2020,130(1):404-421.
[34]	Ren H,Yang X,Yang Y,et al. Upregulation of LncRNA BCYRN1 promotes tumor progression and enhances EpCAM expression in gastric carcinoma[J]. Oncotarget,2017,9(4):4851-4861.
[35]	Huo W,Qi F,Wang K. Long non-coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11[J]. Oncol Rep,2020,44(3):1233-1245.
[36]	Lang N,Wang C,Zhao J,et al. Long non-coding RNA BCYRN1 promotes glycolysis and tumor progression by regulating the miR-149/PKM2 axis in non-small-cell lung cancer[J]. Mol Med Rep,2020,21(3):1509-1516.
[37]	Yu J H,Chen Y. Clinical significance of lncRNA BCYRN1 in colorectal cancer and its role in cell metastasis[J]. Eur Rev Med Pharmacol Sci,2019,23(21):9371-9378.
[38]	Ghafouri Fard S,Dashti S,Hussen B M,et al. BCYRN1:An oncogenic lncRNA in diverse cancers[J]. Pathol Res Pract,2021,220(4):153385.
[39]	Zheng H,Chen C,Luo Y,et al. Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer[J]. Clin Transl Med,2021,11(7):e497.
[40]	Luo G,Zhang Y,Wu Z,et al. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis[J]. Acta Biochim Biophys Sin (Shanghai),2021,53(5):558-566. doi: 10.1093/abbs/gmab023
[41]	Crowley E,Di Nicolantonio F,Loupakis F,et al. Liquid biopsy:monitoring cancer-genetics in the blood[J]. Nat Rev Clin Oncol,2013,10(8):472-484. doi: 10.1038/nrclinonc.2013.110
[42]	Su Q,Wu H,Zhang Z,et al. Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer[J]. Front Oncol,2021,11(15):719863.
[43]	Li W X,Zhang Y L. Novel long non-coding RNA markers for prognostic prediction of patients with bladder cancer[J]. Chin Med Sci J,2020,35(3):239-247. doi: 10.24920/003662
[44]	Zhang S,Du L,Wang L,et al. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer[J]. J Cell Mol Med,2019,23(2):1396-1405. doi: 10.1111/jcmm.14042
[45]	Zhan Y,Du L,Wang L,et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer[J]. Mol Cancer,2018,17(1):142. doi: 10.1186/s12943-018-0893-y
[46]	Yazarlou F,Modarressi M H,Mowla S J,et al. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer[J]. Cancer Manag Res,2018,10(22):6357-6365.
[47]	Abbastabar M,Sarfi M,Golestani A,et al. Tumor-derived urinary exosomal long non-coding RNAs as diagnostic biomarkers for bladder cancer[J]. EXCLI J,2020,19(1):301-310.
[48]	Wang J,Gao Y,Wang X,et al. Circulating lncRNAs as noninvasive biomarkers in bladder cancer:A diagnostic meta-analysis based on 15 published articles[J]. Int J Biol Markers,2020,35(2):40-48. doi: 10.1177/1724600820926685
[49]	Wang J,Yang K,Yuan W,et al. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis[J]. Med Sci Monit,2018,24(12):9307-9316.
[50]	Berrondo C,Flax J,Kucherov V,et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes[J]. PLoS One,2016,11(1):e0147236. doi: 10.1371/journal.pone.0147236

相关文章(20)

[1]	刘玉芹, 杨明莹, 王留芳, 夏斯亚, 李丹娜, 赵喜娟, 王娅. 膀胱癌患者报告结局量表的编制与信效度检验, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240727
[2]	安义均, 余立丹, 赵美素, 马冬梅, 杨春花, 孔瑶. 膀胱癌溶酶体相关基因的预后模型构建与分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240510
[3]	谢飞飞, 辛隐子, 徐敏, 李景涵, 王伟. 长链非编码RNA在软骨发育及骨关节炎中作用机制的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241001
[4]	谢峻, 刘绍有, 施鸿金, 毛秋玉, 杨宏. EZH2抑制剂与膀胱癌GC化疗药物联用增敏的作用研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231017
[5]	陈诗, 付什, 谭智勇, 王剑松, 王海峰. 自噬在膀胱癌发展和治疗中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230503
[6]	张梁, 王保全, 雷喜锋, 王旭, 柯阳, 张玮. M2巨噬细胞来源的外泌体miR-1246调控胃癌细胞的生长和侵袭, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230724
[7]	曹诗杰, 安红伟. MSC来源外泌体治疗缺血性脑卒中机制及进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230913
[8]	董昊楠, 王海峰, 黄应龙, 施鸿金, 毛岚, 刘毅杰, 王剑松. 根治性膀胱切除原位新膀胱术后代谢并发症及处理研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221229
[9]	严植, 郝金钢, 尚芸芸. VI-RADS评分对膀胱癌精准治疗的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220322
[10]	郭方圆, 李文亮, 徐凡, 魏向群. 非编码RNA 在宫颈癌组织中的表达及临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220527
[11]	张天红, 杨红菊. 外泌体miRNA在肝细胞癌中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220221
[12]	马丽娅, 饶南荃, 杨禾丰. 间充质干细胞外泌体在口腔组织再生中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210527
[13]	蔡啸, 扆雪涛, 姚菁青, 戴昕妤, 汤忠泉, 欧婷, 赵晓敏, 李云涛. 人骨髓间充质干细胞分泌的外泌体调控恶性胶质瘤相关巨噬细胞的极化, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210101
[14]	张腾飞, 何越峰, 张磊, 张莉, 杨凯云, 刘莲清, 谭慧. 长链非编码RNA APTR、HEIH、FAS-ASA1、FAM83H-AS1、DICER1-AS1、PR-lncRNA在肺癌中的表达, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210409
[15]	於晓东, 龙江. 12外泌体对体外血脑屏障模型功能的影响, 昆明医科大学学报.
[16]	杨灿, 巩宇航, 王海峰, 李海皓, 刘靖宇, 王伟, 王剑松, 左毅刚, 陈戬, 詹辉, 丁明霞. 单抗KMP1的体内抑制膀胱癌EJ细胞株成瘤的动物实验, 昆明医科大学学报.
[17]	雷玉英, 高洁, 王饶祥, 钏莉雪, 郝金钢. 弥散加权成像在膀胱癌诊断的价值, 昆明医科大学学报.
[18]	黄振华, 石鑫, 王辉涛, 张劲松, 王光, 郝金刚, 刘建和. 磁共振弥散加权成像在膀胱癌T分期的应用价值, 昆明医科大学学报.
[19]	马真. 改良型TAT-VP3融合蛋白对膀胱癌BIU-87细胞Bcl-2和Survivin表达的影响, 昆明医科大学学报.
[20]	. 肌层浸润性膀胱癌的治疗策略, 昆明医科大学学报.